With the completion of clinical trials that demonstrated excellent results, the primary indigenous drug to treat COVID-19 named Vincov-19 is anticipated to be made available to the general public soon.
CSIR-Centre for Cellular & biological science (CCMB), VINS Bioproducts and the University of Hyderabad (UoH) has collaborated to make the drug, Vincov-19.
To create this drug, the foremost step taken was the SARS-CoV-2 virus was inactivated and injected into horses. Then the anti-bodies that are generated through the bodily fluid are synthesized to purify and produce a drug. This drug is later on injected into humans to neutralise the COVID virus.
The CCMB is an Indian fundamental bioscience research institute based in Hyderabad. UNESCO’s Global Molecular and Cell Biology Network have designated CCMB as a “Centre of Excellence.” It is a number one research institute that conducts high-quality basic research and training in areas of recent biology, in addition to promoting centralised national facilities for new techniques in interdisciplinary fields of biology. It was established as a semi-autonomous centre on April 1, 1977.
The pandemic has demonstrated that the country must become self-sufficient in terms of healthcare, instead of relying only on imports. CCMB and other scientific institutes rose to the challenge in a very short period of your time, developing diagnostic kits, testing facilities, gadgets, genomics, and deals on over 170 possible regents and medicines.